Article

The Evolving Role of PI3K Inhibitors in the Treatment of Follicular Lymphoma

On June 18, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of follicular lymphoma to participate in a virtual workshop to discuss the evolving role of PI3K inhibitors in the treatment of follicular lymphoma. This article summarizes key data about PI3K inhibitors as a therapeutic target as well as insights from stakeholder discussions regarding this topic.

Download PDF
Related Videos
Sarah Sammons, MD
Laura Spring, MD
Laura Spring, MD
Corey J. Langer, MD
John F. Lazar, MD
Rodolfo Bordoni, MD
Brad S. Kahl, MD, of Siteman Cancer Center
John P. Leonard, MD, of Weill Cornell Medicine
John P. Leonard, MD, of Weill Cornell Medicine
Related Content
Best Practices in Treating Early-Stage NSCLC
July 11th 2024

Best Practices in Treating Early-Stage NSCLC

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer
April 11th 2024

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer
April 21st 2023

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

Clinical Decision Making in Advanced NSCLC without Actionable Mutations
April 21st 2023

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

BTK Inhibitors in MCL and CLL
March 10th 2023

BTK Inhibitors in MCL and CLL

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?
January 25th 2023

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?